Zhi-Xing Fan1,2,3,4, Jun Yang1,2,3, Jing Zhang1,2,3, Chao He1,2,3, Hui Wu1,2,3, Chao-Jun Yang1,2,3, Tao Zheng1,2,3, Cong Ma1,2,3, Zu-Jin Xiang1,2,3, Yu-Hong Zhai1,2,3, Jing Jiang5, Shao-Qin Qiu6, Jian Yang7. 1. Department of Cardiology, the First College of Clinical Medical Sciences, China Three Gorges University & Yichang Central People's Hospital, Yichang, China. 2. Central Laboratory, the First College of Clinical Medical Sciences, China Three Gorges University & Yichang Central People's Hospital, Yichang, China. 3. Yichang Key Laboratory of Ischemic Cardiovascular and Cerebrovascular Disease Translational Medicine, Yichang, China. 4. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. 5. Yichang Center for Disease Control and Prevention, Yichang, China. 6. Department of Cardiology, Yichang Third People's Hospital, Yichang, China. 7. Department of Cardiology, the People's Hospital of Three Gorges University & the First People's Hospital of Yichang, Yichang, China.
Abstract
BACKGROUND: Cardiac injury is a common condition among hospitalized coronavirus disease 2019 (COVID-19) patients, and is associated with a higher risk of mortality. However, the mechanism of myocardial injury in COVID-19 remains unclear. In this retrospective study, we compared the clinical characteristics of COVID-19 patients with different troponin I (TnI) levels during hospitalization to provide a clinical reference for the identification of those at high-risk. METHODS: In total, 218 patients diagnosed with COVID-19 in Yichang Central People's Hospital and Yichang Third People's Hospital between January 23 and February 19, 2020 were initially included. Of these patients, 89 underwent TnI testing during hospitalization and were finally included in the study. The medical history, clinical signs and symptoms at the time of admission, and laboratory test results were recorded. The patients were assigned to the normal TnI group (TnI <0.01 µg/L; n=67) or the elevated TnI group (TnI >0.01 µg/L; n=22). RESULTS: The incidence of elevated TnI in our patient cohort was 24.7%. There were significant differences between the two groups in the following factors: history of coronary heart disease (CHD), age, lymphocyte count, prothrombin time (PT), activated partial thromboplastin time (APTT), and levels of interleukin (IL)-6, C-reactive protein (CRP), myoglobin (MYO), lactate dehydrogenase (LDH), and albumin (all P<0.05). Binary logistic analysis showed that a history of CHD, age, lymphocyte count, IL-6, APTT, and MYO were influencing factors of elevated serum TnI. CONCLUSIONS: A history of CHD, advanced age, decreased lymphocyte count, increased IL-6, increased MYO, and prolonged APTT were independent influencing factors of elevated TnI in COVID-19 patients. COVID-19 patients with these characteristics are prone to myocardial injury. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Cardiac injury is a common condition among hospitalized coronavirus disease 2019 (COVID-19) patients, and is associated with a higher risk of mortality. However, the mechanism of myocardial injury in COVID-19 remains unclear. In this retrospective study, we compared the clinical characteristics of COVID-19 patients with different troponin I (TnI) levels during hospitalization to provide a clinical reference for the identification of those at high-risk. METHODS: In total, 218 patients diagnosed with COVID-19 in Yichang Central People's Hospital and Yichang Third People's Hospital between January 23 and February 19, 2020 were initially included. Of these patients, 89 underwent TnI testing during hospitalization and were finally included in the study. The medical history, clinical signs and symptoms at the time of admission, and laboratory test results were recorded. The patients were assigned to the normal TnI group (TnI <0.01 µg/L; n=67) or the elevated TnI group (TnI >0.01 µg/L; n=22). RESULTS: The incidence of elevated TnI in our patient cohort was 24.7%. There were significant differences between the two groups in the following factors: history of coronary heart disease (CHD), age, lymphocyte count, prothrombin time (PT), activated partial thromboplastin time (APTT), and levels of interleukin (IL)-6, C-reactive protein (CRP), myoglobin (MYO), lactate dehydrogenase (LDH), and albumin (all P<0.05). Binary logistic analysis showed that a history of CHD, age, lymphocyte count, IL-6, APTT, and MYO were influencing factors of elevated serum TnI. CONCLUSIONS: A history of CHD, advanced age, decreased lymphocyte count, increased IL-6, increased MYO, and prolonged APTT were independent influencing factors of elevated TnI in COVID-19 patients. COVID-19 patients with these characteristics are prone to myocardial injury. 2020 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Chhinder P Sodhi; Christine Wohlford-Lenane; Yukihiro Yamaguchi; Thomas Prindle; William B Fulton; Sanxia Wang; Paul B McCray; Mark Chappell; David J Hackam; Hongpeng Jia Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-09-21 Impact factor: 5.464
Authors: Jacqueline E Tamis-Holland; Hani Jneid; Harmony R Reynolds; Stefan Agewall; Emmanouil S Brilakis; Todd M Brown; Amir Lerman; Mary Cushman; Dharam J Kumbhani; Cynthia Arslanian-Engoren; Ann F Bolger; John F Beltrame Journal: Circulation Date: 2019-04-30 Impact factor: 29.690
Authors: Elissa Driggin; Mahesh V Madhavan; Behnood Bikdeli; Taylor Chuich; Justin Laracy; Giuseppe Biondi-Zoccai; Tyler S Brown; Caroline Der Nigoghossian; David A Zidar; Jennifer Haythe; Daniel Brodie; Joshua A Beckman; Ajay J Kirtane; Gregg W Stone; Harlan M Krumholz; Sahil A Parikh Journal: J Am Coll Cardiol Date: 2020-03-19 Impact factor: 24.094
Authors: Alaa Hasan Alali; Mustafa Samir Smaisem; Ahmed Mohammed Alsheikh; Aljohara Abdullah Alshareef; Fatema Samir Smaisem; Batool Wael Alnahar; Amal Khalil Hassouneh; Jaffar A Al-Tawfiq; Ziad A Memish Journal: Infez Med Date: 2021-09-10